-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HhBrYQEzvKucEICH4O4VCgN4IS7h6HnlVoeGD7OthxFB8h4C8evMC/vO0YtCGrWu /rmGGar63amEk378fmLaRg== 0001181431-10-038099.txt : 20100721 0001181431-10-038099.hdr.sgml : 20100721 20100721132641 ACCESSION NUMBER: 0001181431-10-038099 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100608 FILED AS OF DATE: 20100721 DATE AS OF CHANGE: 20100721 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KLEIN JOSEPH III CENTRAL INDEX KEY: 0001206369 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 10962055 MAIL ADDRESS: STREET 1: C/O GENAISSANCE PHARMACEUTICALS INC STREET 2: FIVE SCIENCE PARK CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 4/A 1 rrd281597.xml FORM 4/A FOR JOSEPH KLEIN III X0303 4/A 2010-06-08 2010-06-10 0 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001206369 KLEIN JOSEPH III SAVIENT PHARMACEUTICALS, INC. ONE TOWER CENTER, 14TH FLOOR EAST BRUNSWICK NJ 08816 1 0 0 0 Common Stock, $.01 par value per share 2010-06-08 4 A 0 3514 D 17388 D The right to receive these shares is pursuant to a restricted stock unit grant, 100% of which shall vest 30 days from the first anniversary of the Company's 2010 Annual Meeting of Stockholders. Mr. Klein has elected to defer receipt of such shares upon vesting until the earliest of his death, disability or retirement from the Board of Directors of the Company, a change of control of the Company and ten years from the date of vesting of such shares. Due to administrative error, Mr. Klein was reported in a filing on June 10, 2010 to have acquired 3,514 shares of restricted stock on June 8, 2010. Mr. Klein received these restricted stock units as a grant forming part of his annual compensation as a director of the company and for no consideration. The restricted stock units had an aggregate fair market value of $39,989.32 based on the $11.38 per share closing price of the Company's common stock as quoted by the Nasdaq Global Market on the date of grant. /s/ Philip K. Yachmetz as Attorney-In-Fact for Joseph Klein III 2010-07-21 -----END PRIVACY-ENHANCED MESSAGE-----